Immunopotentiating conjugates.
Current interest in the development of sub-cellular vaccines and in cancer immunotherapy has rekindled interest in immunopotentiating agents. In addition, peptide sequences of protective antigens are being synthesized or genetically engineered and it is likely that these peptides will have a small relative molecular mass and be non-immunogenic by themselves. A variety of experimental studies have shown that such protective antigens could be included in conjugated vaccines with carrier protein and/or immunopotentiator. The insertion of peptides with hydrophobic sequences into artificial lipid bilayers (liposomes) offers another mode of presentation of antigen to the immune system.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology; D002473:Cell Wall / Q000276:immunology; D006801:Humans; D008081:Liposomes; D014612:Vaccines / Q000008:administration & dosage
D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D008081:Liposomes; D014612:Vaccines; D000119:Acetylmuramyl-Alanyl-Isoglutamine